Combined electronic nudges effectively facilitate serious illness conversations between patients with cancer and their ...
In patients with previously treated advanced/metastatic KRAS G12C NSCLC, divarasib improves survival compared with sotorasib ...
Pembrolizumab continues to demonstrate a disease-free and overall survival benefit for patients with clear cell renal ...
Niraparib plus dostarlimab with definitive cisplatin plus radiotherapy improves some outcomes in patients with locally ...
The conversion from accelerated to traditional approval updates the tumor mutational burden threshold from 10 to 13 mutations/megabase based on confirmatory KEYNOTE-158 data.
Socioeconomic disadvantage, disease presentation, and treatment differences are key contributors to rural-urban mortality gap ...
(HealthDay News) — State health officials fighting measles outbreaks this spring asked the US Centers for Disease Control and Prevention (CDC) for help getting a faster test. The agency took 2 months ...
In patients with extensive-stage small cell lung cancer, adding tarlatamab to durvalumab maintenance therapy significantly ...
In patients with muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant durvalumab and enfortumab vedotin, with or ...
The intismeran/pembrolizumab combination significantly improved relapse-free and distant metastasis-free survival in advanced ...
Nivolumab-ipilimumab prolongs OS compared to nivolumab alone or chemo in MSI-H or dMMR, unresectable or metastatic colorectal ...
Updated findings from the OptimUM trials support the use of darovasertib plus crizotinib in the treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results